Mariam Vahdaninia1, Healther Mackenzie2, Taraneh Dean3, Suzannah Helps2. 1. Bournemouth University, Faculty of Health and Social Sciences, United Kingdom; University of Portsmouth School of Health Sciences and Social Work, Portsmouth, Hampshire, United Kingdom. Electronic address: mvahdaninia@bournemouth.ac.uk. 2. University of Portsmouth School of Health Sciences and Social Work, Portsmouth, Hampshire, United Kingdom. 3. University of Portsmouth School of Health Sciences and Social Work, Portsmouth, Hampshire, United Kingdom; University of Brighton, Research and Enterprise, Eastbourne, Hastings, United Kingdom.
Abstract
BACKGROUND: Allergic diseases have increased worldwide in the last 2 decades, with children suffering the highest burden of the condition. The ω-3 long-chain poly-unsaturated fatty acid (LCPUFA) possesses anti-inflammatory properties that could lead to a reduction in inflammatory mediators in allergies. OBJECTIVE: A systematic review and meta-analysis of the most recent follow-ups of randomized clinical trials (RCTs) was conducted to assess the effectiveness of ω-3 LCPUFA supplementation started during pregnancy on allergic outcomes in offspring. METHODS: The RCTs with a minimum of 1-month follow-up post gestation were eligible for inclusion. The CENTRAL, MEDLINE, SCOPUS, WHO's International Clinical Trials Register, E-theses, and Web of Science databases were searched. Study quality was evaluated using the Cochrane Collaboration's risk of bias tool. RESULTS: Ten RCTs (3,637 children), from 9 unique trials, examined the effectiveness of ω-3 LCPUFA supplementation started during pregnancy on the development of allergic outcomes in offspring. Heterogeneities were seen between the trials in terms of their sample, type, and duration of intervention and follow-up. Pooled estimates showed a significant reduction in childhood "sensitization to egg" (relative risk [RR] = 0.54, 95% confidence interval [CI] = 0.32-0.90), and "sensitization to peanut" (RR = 0.62, 95% CI = 0.40-0.96). No statistical differences were found for other allergic outcomes (eg, eczema, asthma/wheeze). CONCLUSION: These results suggest that intake of ω-3 LCPUFA started during pregnancy can reduce the risk of sensitization to egg and peanut; however, the evidence is limited because of the small number of studies that contributed to the meta-analyses. The current evidence on the association between supplementation with ω-3 LCPUFA started during pregnancy and allergic outcomes is weak, because of the risk of bias and heterogeneities between studies.
BACKGROUND:Allergic diseases have increased worldwide in the last 2 decades, with children suffering the highest burden of the condition. The ω-3 long-chain poly-unsaturated fatty acid (LCPUFA) possesses anti-inflammatory properties that could lead to a reduction in inflammatory mediators in allergies. OBJECTIVE: A systematic review and meta-analysis of the most recent follow-ups of randomized clinical trials (RCTs) was conducted to assess the effectiveness of ω-3 LCPUFA supplementation started during pregnancy on allergic outcomes in offspring. METHODS: The RCTs with a minimum of 1-month follow-up post gestation were eligible for inclusion. The CENTRAL, MEDLINE, SCOPUS, WHO's International Clinical Trials Register, E-theses, and Web of Science databases were searched. Study quality was evaluated using the Cochrane Collaboration's risk of bias tool. RESULTS: Ten RCTs (3,637 children), from 9 unique trials, examined the effectiveness of ω-3 LCPUFA supplementation started during pregnancy on the development of allergic outcomes in offspring. Heterogeneities were seen between the trials in terms of their sample, type, and duration of intervention and follow-up. Pooled estimates showed a significant reduction in childhood "sensitization to egg" (relative risk [RR] = 0.54, 95% confidence interval [CI] = 0.32-0.90), and "sensitization to peanut" (RR = 0.62, 95% CI = 0.40-0.96). No statistical differences were found for other allergic outcomes (eg, eczema, asthma/wheeze). CONCLUSION: These results suggest that intake of ω-3 LCPUFA started during pregnancy can reduce the risk of sensitization to egg and peanut; however, the evidence is limited because of the small number of studies that contributed to the meta-analyses. The current evidence on the association between supplementation with ω-3 LCPUFA started during pregnancy and allergic outcomes is weak, because of the risk of bias and heterogeneities between studies.
Authors: Carina Venter; Carlo Agostoni; S Hasan Arshad; Miriam Ben-Abdallah; George Du Toit; David M Fleischer; Matthew Greenhawt; Deborah H Glueck; Marion Groetch; Nonhlanhla Lunjani; Kate Maslin; Alexander Maiorella; Rosan Meyer; Muraro Antonella; Merryn J Netting; Bright Ibeabughichi Nwaru; Debra J Palmer; Micheala P Palumbo; Graham Roberts; Caroline Roduit; Pete Smith; Eva Untersmayr; Lauren A Vanderlinden; Liam O'Mahony Journal: Pediatr Allergy Immunol Date: 2020-08-06 Impact factor: 5.464
Authors: Sara M Mensink-Bout; Trudy Voortman; Marsela Dervishaj; Irwin K M Reiss; Johan C De Jongste; Vincent W V Jaddoe; Liesbeth Duijts Journal: Nutrients Date: 2020-10-07 Impact factor: 5.717
Authors: Matthias V Kopp; Cathleen Muche-Borowski; Michael Abou-Dakn; Birgit Ahrens; Kirsten Beyer; Katharina Blümchen; Petra Bubel; Adam Chaker; Monika Cremer; Regina Ensenauer; Michael Gerstlauer; Uwe Gieler; Inga-Marie Hübner; Fritz Horak; Ludger Klimek; Berthold V Koletzko; Sybille Koletzko; Susanne Lau; Thomas Lob-Corzilius; Katja Nemat; Eva M J Peters; Antonio Pizzulli; Imke Reese; Claudia Rolinck-Werninghaus; Elien Rouw; Bianca Schaub; Sebastian Schmidt; Jens-Oliver Steiß; Anne Kathrin Striegel; Zsolt Szépfalusi; Dietmar Schlembach; Thomas Spindler; Christian Taube; Valérie Trendelenburg; Regina Treudler; Ulrich Umpfenbach; Christian Vogelberg; Martin Wagenmann; Anke Weißenborn; Thomas Werfel; Margitta Worm; Helmut Sitter; Eckard Hamelmann Journal: Allergol Select Date: 2022-03-04